

Review of TA414; Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Decision

The guidance remains relevant and an update is not needed.

Background

TA414 was published in October 2016 (see appendix A) and scheduled to be considered for review in 2019.

Stakeholders were asked whether the guidance is still relevant and whether there is new evidence that would affect the recommendations (see appendix B).

Based on the information received, we found nothing new that affects the existing recommendations. The guidance remains relevant and an update is not needed.

This may change if NICE becomes aware of new evidence that would make it reconsider.

Decision paper sign off

Jennifer Prescott – Programme Director, Planning and Operations

20 May 2020

Contributors to this paper

Project manager: Charlotte Downing

Appendix A – Information from existing guidance

Original remit

To appraise the clinical and cost effectiveness of cobimetinib in combination with vemurafenib within its marketing authorisation for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma.

Current guidance

1.1 Cobimetinib in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

1.2 This guidance is not intended to affect the position of patients whose treatment with cobimetinib in combination with vemurafenib was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

Appendix B – Stakeholders asked to comment

Stakeholders who agree that the guidance should remain unchanged

- Novartis Pharmaceuticals Ltd
- Roche Products Limited

No response received from:

- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Association of Cancer Physicians
- Black Health Agency
- Board of Community Health Councils in Wales
- British Association of Dermatologists
- British Association of Skin Cancer Specialist Nurses
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute of Radiology
- British National Formulary
- British Psychosocial Oncology Society
- British Skin Foundation
- British Skin Foundation
- British Society for Dermatological Surgery
- Cancer 52
- Cancer Black Care
- Cancer Equality
- Cancer Research UK
- Care Quality Commission
- Cochrane Skin Group
- Department of Health and Social Care
- Department of Health, Social Services and Public Safety for Northern Ireland
- Equalities National Council

- Healthcare Improvement Scotland
- Helen Rollason Cancer Charity
- Independent Cancer Patients' Voice
- Institute of Cancer Research
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie
- Medicines and Healthcare products Regulatory Agency
- Melanoma Focus
- Melanoma Fund
- Melanoma UK
- MRC Clinical Trials Unit
- Muslim Council of Britain
- National Association of Primary Care
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- NHS England
- NHS Somerset CCG
- NHS South Eastern Hampshire CCG
- OcuMelUK
- Primary Care Dermatology Society
- Public Health England
- Public Health Wales
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists

- Royal Pharmaceutical Society
- Royal Society of Medicine
- Scottish Medicines Consortium
- Skcin - Karen Clifford Skin Cancer Charity
- Skin Cancer Research Fund
- Skin Treatment & Research Trust
- Society and College of Radiographers
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Welsh Government
- Welsh Health Specialised Services Committee